SlideShare a Scribd company logo
Medical management
By Dr.Sudha Shahi
Dept of ENT Head and Neck Surgery
Bir Hospital ,NAMS
Kathmandu,Nepal
 “When we consider the quality of life impact from
RS related symptoms and the associated emotional
and functional impairments it can be assumed that
RS has a dramatic impact on peoples lives and in
productivity of life.”
Brief Recall:
Rhinosinusitis-
Group of disorders characterised by Inflammation of
mucosa of nose and paranasal sinuses.
Allergy
Intermittent(Seasonal AR)
Persisitent(Perennial AR)
Infection
Acute( 7 days to <4wks)
Viral (majority of cases)
Subacute(4-12wks)
Chronic(>12wks)
Recurrent acute – 4 or more episodes per year, with resolution of
symptoms between attacks
Acute Exacerbation of Chronic- Sudden worsening of CRS with
return to baseline after
Others
Occupational irritants and allergens
Vasculitis/granulomatous/autoimmune
Aspirin sensitivity
Allergic fungal sinusitis
Atrophic rhinitis
 Others
NARES
Drug induced, rhinitis medicamentosa
Irritant-induced rhinitis
GERD
Underlying diseases(cystic fibrosis, ciliary immotility)
Structural
 Osteomeatal complex
 Deviated nasal septum
 Hypertrophic turbinates
Idiopathic
LETS DO
STH
HERE
TIME FOR
SOME AB
Allergic Rhinitis
 Allergen avoidance
 Antihistamines:
 First generation mostly avoided d/t sedative
psychomotor retardation and learning impairment d/t
BBB crossing nature of it as compared to
Cetrizine,Fexofenadine,desloratidine .Also possess some
antiinflammatory effect
 Topical Glucorticosteroid:
Best is started before allergen exposure .
Reduce inflammation,hyperreactivity and sense of smell
Sodium chromoglycate :
Used for children below 4 yrs in whom topical
corticoseroid is not used often
Decongestants:
Reduce nasal obstruction but long term use might
cause rhinitis medicamentosa
Ipratropium bromide:
Symptomatic relief in rhinorrhea but careful use in
glaucoma and prostatism and might worsen dry
eyes and mouth
Systemic Corticosteroids
Occasional intermittent use combined with topical CS
Antileukotrienes:
Effective against congestion and mucus
production.Combined with antihistamine has better
benefits.
Nasal douching :
Helps provide symptomatic relief and clear up the
sinuses
Immunotherapy:
Only in selective patients with limited spectrum of
allergies
~ 40% reduction in symptoms and ~80% reduction in
rescue medication requirements
Also helpful in associated bronchial Asthma
Nevertheless patients with chronic Asthma are
excluded from the treatment due to risk of many
side effects
Inclusion criteria
 IgE-mediated disease
(+SPT/RAST)
 Inability to avoid allergen
 Inadequacy of drug
 Limited spectrum of
allergies (one or two)
 Patients who understand
risks and limitations of
treatment
Contraindications
 Coexistent asthma
 Patients taking beta-
blockers
 Other
medical/immunologic
 Small children (less than
five years)
 Pregnancy (maintenance
therapy may be continued
in pregnancy)
Novel advances
 Sublingual immunotherapy
 Bacterial DNA sequences conjugated with allergen
induces preferential TH1 response and protective T
cell response
 Surgery:
 Very limited role and required only in conditions
where there is marked septal deviation or bony
turbinate enlargement which makes topical nasal
sprays usage difficult.
Acute Rhinosinusitis Treatment
Viruses
Rhinovirus
Coronaviruses
Influenza virus
Parainfluenza virus
Adenovirus
RSV
Enterovirus
Children Adults
Streptococcus pneumoniae (30-43%)
Haemophilus influenzae (20-28%)
Moraxella catarrhalis (20-28%)
Other Streptococcus species (5-7%)
Anaerobes(5-7%)
Streptococcus pneumoniae (20-43%)
Haemophilus influenzae (22-35%)
Streptococcus species (3-9%)
Anaerobes (0-9%)
Moraxella catarrhalis (2-10%)
Staphylococcus aureus (0-8%)
Others(4%)
Common for all types of Acute RS:
Hydration
Long-acting topical nasal decongestant
Nasal saline applied with nasal irrigation
device
Topical nasal CCS
Antibiotics in Acute bacterial
rhinosinusitis
Don’t treat common viral cold with antibiotic
Reserve for severe, presumably bacterial
Rhinosinusitis
symptoms past 7-10 days:
Antibiotics X 7-14 days (until asymptomatic +5-7 days).
Choices:
Amoxicillin/clavulanate, Cephalosporin, Clarithromycin
First choice:
Amoxicillin/clavulate or cephalosporin
Good second choice: Clarithromycin
(Azithromycin, 5-0-(5), may also be quite useful)
Back-ups:
Quinolones
Use Metronidazole plus one of the above or
clindamycin when gram negative is suspected
Topical mupirocin very useful in select cases
EPOS JTFPP CPG AS
Uncomp
icated
AVRS
Mild Disease-
Symptoms lasting <5d or
improving thereafter
Decongestants ,Saline or
analgesics
Moderately severe-
Symptoms lasting >.5d or
increasing
Add topical corticosteroids
If no improvement after 14
d
Reconsider rediagnosis
Consider nasal endoscopy
Culture/imaging
Consider antibiotics if
necessary
Severe Disease-
Severe pain and temp >38
Add antibiotics and topical
corticosteroids for 7-14 days
(expected results in 48 hrs)
7-10 days course of
watchful waiting
Antibiotics are
strongly
discouraged
Management primarily
symptomatic
Analgesics and
antipyretics
Oral or topical
decongestants
Topical nasal
CS(Optional)
EPOS JTFFP CPG AS
Uncomplicate
d ABRS
Mild Disease-
Symptoms lasting <5d or
improving thereafter
Decongestants ,Saline or
analgesics
Moderately severe-
Symptoms lasting >.5d or
increasing
Add topical corticosteroids
If no improvement after 14 d
Reconsider rediagnosis
Consider nasal endoscopy
Culture/imaging
Consider antibiotics if
necessary
Severe Disease-
Severe pain and temp >38
Add antibiotics and topical
corticosteroids for 7-14 days
(expected results in 48 hrs)
Antibiotics 10-14 d
Choice of agent
based on likely
pathogen consistent
with clinical history
Consider patients
with severe signs
and symptoms at
any time of the
disease (worsening
after 3-5
days,temp>38,
severe facial
pain,unilateral facial
swelling ,sinus
tenderness)
Assess pain and
analgesics
accordingly
Watchful waiting (
without antibiotic i
symptom< 7d)or
mild disease or if pt
likely to F/U
Initiate Antibiotics i
no improvement
after 7d or if it
worsen (Amoxy firs
line)Antibiotics if
severe disease
Antihistamine
Donot use if
nonatopic
symptomatic relief i
recommended
EPOS JTFFP CPS AG
ARS in general Intranasal
corticosteroids
Oral CS in severe
disease
Antihistamines
only in allergic
and
Decongestants
Intranasal CS
modestly
benefitial as
adjunctive
therapy in
patients with
reccurent disease
Antihistamines
No data to
recommend use
Topical oral
decongestants
Do not use since
prospective study
ecaluating use are
lacking
Topical CS
optional
Decongestant
optional
Nasal saline
irrigation
optional
Conclusion
 Guidelines promulgated by 5 major groups regarding
acute rhinosinusitis (ARS)
 The efficacy of intranasal corticosteroids has been well
established by clinical trial data, and guidelines advise
their use in ARS
 Physicians have been overusing antibiotics which has
been playing a role in resistance
 The aim of treatment is to reduce signs and
symptoms ,quality of life of patient and prevent the
recurrence.
Chronic inflamed mucosa
Neutrophils and mononuclear cells in CRSsNP
Eosinophils in CRSwNP
Possible chronic infection
Bacteria
Fungi
Superantigens
Biofilms
Osteitis
Children Adults
Anaerobes
Other Streptococcus species
Staphylococcus aureus
Streptococcus pneumoniae
Haemophilus influenzae
Pseudomonas aeruginosa
Anaerobes
Other Streptococcus species
Haemophilus influenzae
Staphylococcus aureus
Streptococcus pneumoniae
Moraxella catarrhalis
Common organisms in CRS
Chronic
Rhinosinusitis Nasal Polyps
Nasal Polyps
The spectrum of sinus disease
Rhinosinusitis
- Eosinophils +
Treatment
Few well-conducted clinical trials in chronic
rhinosinusitis. Further studies are needed in well-
characterized patients.
Based on the evidence available initial therapy is
medical
Aim to reduce symptoms and signs decrease
morbidity and prevent disease progression or
recurrence.
CRS usually responds incompletely to therapy and
may need to be continued long-term
Hydration (6 - 8 glasses of water per day)
Antibiotics only if clear evidence of infection: use X 14-21+
days (until asymptomatic +7 days).
Choices: cephalosporin, amoxicillin/clavulanate,
clarithromycin, quinalone
Long-acting nasal decongestant, BID X 3-7 days
(oxymetazoline)
Nasal saline with nasal irrigation device
Topical nasal CCS
Reduce to lowest effective dose, to maintain remission
Prevalence approx. 2- 4%, 25% of CRS
Asthma in approx. 40-65%
Aspirin sensitivity in 10-15%
Mixed cellular infiltrate with
prominent eosinophilia in 90%
Inflammation with
 local IgE production
 increased IL-5, eotaxin,
cys-LTs and ECP
Treatment of underlying condition
Continue treatment of sinusitis
Topical corticosteroids
Pulmicort, budesonide
Budesonide solution (Pulmicort Respules)
Fluticasone (Flovent
Systemic corticosteroids
Prednisone 20-30 mg
Kaliner MA. Current Review of Allergic Diseases. Philadelphia, Pa: Current Medicine, Inc., 1999.
 Antibiotics
 Long term prophylaxis with macrolids group of
drug (8 wks )found to reduce the polyp size ot 50%
in 21 patients and better response in ptns with
normal IgE levels and inversely proportional in
eosinophil count in blood and mucosa
Mupiricin ointment
Topically or dissolved in sinus lavage
Consider oral or topical anti-fungal treatment
Possible benefits in paediatric Upper airway infcetion
Needs more studies
Polypectomy
Medical polypectomy
 All patients should have a trial of medical treatment
before surgery unless the nature of the polyps is in doubt.
 Smaller polyps may respond to topical corticosteroid
only.
 Larger polyps may respond to a medical polypectomy
Medical polypectomy
Prednisolone 0.5mg/kg each morning for 5–10 days
PLUS Betamethasone nasal drops two drops per nostril
tds in the ‘head upside down’ position for 5 days, then
twice daily until the bottle runs out
 Maintenance therapy with fluticasone (drops, spray) or
mometasone (spray) is recommended as these have lower
bioavailability, unlike betamethasone nasal drops .
 All forms of topical INS may delay the re-growth of nasal
polyps. Polyps tend to recur, and it is recommended that
treatment is continued for the long-term.
 However, no evidence for how long treatment should be
continued although this will vary, with more aggressive
inflammatory polyps rich in eosinophils and IL-5
requiring prolonged treatment.
Surgery
 A randomized prospective study of patients with polypoid
or non-polypoid CRS demonstrated that there was no
difference between patients who received medical
treatment (topical corticosteroid, nasal douching and long-term erythromycin)
compared with those who underwent endoscopic sinus
surgery combined with topical nasal steroids.
 , Clinical and Experimental)
CRS without Nasal polyp
Allergen avoidance
 There is no strong evidence regarding its
effectiveness in CRS but mostly in cases with
positive allergic history together with positive SPT it
might be useful.
Nasal douching
Safe, inexpensive,symptomatic relief
Adverse events
Sodium load should be considered in hypertensive
patients.
Place in therapy
Addition to therapy in chronic rhinosinusitis, nasal
polyposis and rhinitis. Effective in primary ciliary
dyskinesia
Neti pots
The Neti pot originated in India in Ayurvedic medicine.(
VALIDATED BY SCIENTIFIC EVIDENCE) Neti is Sanskrit for “nasal
cleansing.”
Nasal irrigation provides short-term symptomatic relief
and may improve nasal mucociliary clearance. It removes
mucus not only from the nose but also from the maxillary
and ethmoid sinuses.
BUT one should be careful not to overdo it.
Topical intra-nasal corticosteroids
 Act by suppression of inflammation at multiple points in the
inflammatory cascade .
Nasal drops are preferable for nasal polyposis and probably
also for chronic rhinosinusitis.
 These should be used in the ‘head upside down’ position in order to reach the
ostiomeatal complex (OMC),
50% of ptns not responding to topical sprays are responsive to
fluticasone nasules
 Adverse events
 Local nasal irritation, sore throat and epistaxis (10% )
(Benzalkonium chloride)
 Hypothalmic-pituitary axis suppression
 Raised intra-ocular pressure (glaucoma)
 Place in therapy
First-line therapy for rhinosinusitis. Topical steroid
drops should be used initially in nasal polyposis and in
cases with severe obstruction.Routinely used in long term
and reduce the recurrence of nasal polyps.
 A suggested regime for adults is 0.5mg/kg
Used for:
 Severe nasal obstruction
 Short-term rescue medication for uncontrolled
symptoms on conventional pharmacotherapy
Systemic glucocorticosteroids.
Oral corticosteroids should be used briefly and always in
combination with a topical nasal corticosteroid.
 Intra-nasal decongestants.
The a1-agonist ephedrine and a2-agonist xylometazoline
are sympathomimetics( increase nasal vasoconstriction).
Combined with a topical corticosteroid such as Dexa-
Rhinaspray duoTM, short term use is helpful in
exacerbations of rhinosinusitis with nasal blockage
 Adverse events
 Regular use can lead to rhinitis medicamentosa with
tachyphylaxis rebound effect.Nasal irritation may increase
rhinorrhoea.
 Place in therapy
Brief use of 10 days is advised
o To avoid rebound effect for eustachian tube dysfunction
when flying
o In children with acute otitis media to relieve middle ear
pain/pressure post –URTI
o To reduce nasal/sinus congestion
o To increase nasal patency before the intranasal administration
of nasal steroids.
Antibiotics
 Role in CRS is still controversial
Two routes;
 Topical –Abandoned due to incidence of hyposmia but use
of tobramycin instilled into maxillary sinuses in cystic
fibrosis is helpful
 Benefitial in upper airway diseases in children
 Short-term (2 weeks) can be used for AE of rhinosinusitis
with or without the guidance of middle meatal swabs
 Long term prophylaxis
 Trials of long-term oral antibiotics (>12 weeks), especially
macrolides, have demonstrated symptomatic and objective
improvement similar to endoscopic sinus surgery
 Reduction in mortality from diffuse panbronchitis and
improved sinus symptoms
 The improvement shown increases with time and may
relate to anti-inflammatory reactions in macrolides.
Anti-leukotrienes
There are no RCTs on the use of anti-leukotrienes in
rhinosinusitis, but efficacy in nasal polyposis has been
demonstrated.(`50 %respond to some degree)
Adverse events
Usually well tolerated; occasional headache,
gastrointestinal symptoms or rashes. Occasional reports
of Churg-Strauss syndrome which may relate more to
steroid withdrawal rather than a direct effect of the drug,
although further long-term evaluation is needed.
Place in therapy
Anti-leukotrienes may be used in patients with aspirin-
sensitive rhinosinusitis, asthma and nasal polyposis. Some
patients with aspirin sensitivity appear to show marked
improvement.
Aspirin desensitisation
 Oral aspirin desensitization followed by regular daily
dosing may cause significant improvement.
 There is some evidence suggesting that oral doses as low
as 100mg daily maybe effective and this could potentially
circumvent some of the adverse effects associated with
oral aspirin.
 However, side-effects including gastrointestinal bleeding
at high doses .The efficacy of the regular administration of
topical intranasal lysine aspirin therapy remains under
investigation.
Nasal
 Lysine aspirin the soluble aspirin used for diagnosis
of aspirin sensitivity has found to have resulted into
prolonged polyp free interval in both aspirin
sensitive and aspirin tolerant patients.
 It has shown to be associated with reduction of
cysteinyl leukotriene receptors which are
upregualted in nasal mucosa of aspirin sensitive
individuals.
Immunotherapy
 Immunoglobulin replacement therapy in humoral
deficiency syndromes( frank hypogammaglobinemia
to IgA and other subclasses deficiencies)
Bacterial vaccines
 Used previously but no strong evidence of benefitial
effect
 Other therapies
Diuretics
 Frusemide found to reduce the recurrence of polyps
if administered nasally to post polypectomy patients
over a prolonged periods
 Similarly amiloride used in cystic fibrosis also
suggested as topical therapy for nasal polyps
Azelastine:
An open study suggests that this may have some benefit in
nasal polyposis
Nitric Oxide donors:
NO has bactericidal properties and is manufactured inPNS.
NO levels are raised in inflammation but decreased in
CRSprobabaly due to ostiomeatal complex obstruction.
hence increased. NO levels is a landmark for successful
therapy.
eg.Arginine
 Diet
 Alcohol,preservative,high salicylate food exacerbate
 Milk mucus promoter
 In case of ocupational ,food induced,drug induced,irritant
induced avoidance of the causitive factor
 Intranasal anticholinergics (Ipratropium bromide)
 Nasal decongestants
 Topical steroids and antihistamines
 Azelastine
 Silver nitrate and botulinum if no response to conventional
therapy
 Intranasl capsacain once daily for 5 weeks
 Surgical aproach if turbinate hypertrophy with resistant with
medical response
 Ethmoid and Vidian neurectomies
Allergic fungal sinusitis
Aggressive nasal Rx
Budesonide nasal washings, 500 ug BID
Itraconazole, oral
100 mg BID x 6 months
100 mg QD x 12 months
Monitor LFT, IgE Q 3 mos
Consider surgery if unresponsive
Surgery with the removal of all affected tissue, followed by
topical corticosteroids
Fungal rhinosinusitis
Open studies of douching with antifungals such as
amphotericin have been reported as beneficial
 Antifungals
 Placebo-controlled trials of amphotericin nasal
douching are negative .
 Oral terbinafine has also failed to show any activity
under double-blind conditions
Churg-Strauss syndrome
 This is a combination of severe asthma, nasal polyposis,
eosinophilia and eosinophilic vasculitis with granulomas.
It should be suspected in patients with severe disease
requiring frequent courses of oral corticosteroids.
About 50% of patients are ANCA positive.). If the
diagnosis of Churg-Strauss syndrome is suspected,
specialist referral to a vasculitis clinic is advisable for
further mangement
Specific Chronic Infections
Nasal Tuberculosis
Lupus vulgaris(nodular forms),Ulcerative forms,sinus
granuloma
 Tubercular treatment ; 4 drug regimen 4HRZE+4HR
Syphilis
TT;Parenteral penicillin preferred DOC
 Local treatment includes crust removal,alkaline nasal
douches ,yellow mercury oxide oint locally
 Hereditary syphillis
 Local cleansing
 Yellow mercury oxide oint.
 Nasal douching
 Antisyphillitic medication
 Leprosy
 Direct intranasal administration of rifampin reduce
M.Leprae load much faster than when given orally
 Rifamicin 600mg first 2 days on alternate days three times
aweek
 Clofazimine 100mg alternate day three times a week
 Dapsone 100mg daily
Atrophic Rhinitis
 Regular nasal cleansing
 Nasal douching with hypertonic alkaline saline
(sodium bicarb:Sodium diborate:sodium chloride)1;1;2 in
280 ml of water followed by solution of 25 percent glucose
in glycerine to inhibit proteolytic organisms
 Human placental extract systemically and locally
 Rifampicin 600mg oral for 12 weeks good results
 Underlying diseases(Cystic fibrosis,Wegners
granulomatosis)
Azathioprine ,cyclophosphamide or cotrimoxazole in
addition to the symtomatic management
Structural
 Obstruction of Osteomeatal complex
 Decongestant
 Nasal douching
 Topical CS
 Review at 6 wks
Further medical therapy
 Oral CS few days plus Topical for long term
 For nasal polyposis
 Trial of leukotriene for nasal polyposis
 Antibiotics
 Aspirin
Rhinosinusitis in children
Common problem;may be related to underlying immune
deficiency (innate or acquired) or to allergy
Like OME, usually resolves with maturation (~7 years)
Medical treatment including douching should be instigated, with
surgery reserved for acute severe problems or for those patients
with severe chronic symptoms not responding to medical therapy
.
Few clinial studies in Rhinosinusitis and their
guidelines brief comparision
EPOS
 CRSsNP
 Mild(VAS 0-3)
 Topical CS
 Nasal Lavage if failure after 3 months treat as moderate
or severe
 Moderate /severe(VAS >3-10)
 Topical CS
 Nasal lavage
 Longterm macrolide therapy
 Culture
 Cases that improve
 Follow up + nasal lavage ,topical CS +/- long term
macrolide therapy
Mild = VAS 0 - 3 Moderate = >3 - 7 Severe = VAS >7 - 10
 CRScNP
Mild (VAS 0-3)
 TopicalCS sprayfor 3 months
 if benefitial continue and review every 6 months
 If no improvement ,add short course of oral CS
 If still n oimprovement ,consider CT assess as
surgical candidate
 If improved after 1 month switch to topical CS
drops,review after 3 months
Moderate (VAS 3-7)
 Topical CS drops for 3 months
 if beneficial continue and review every 6 months
 If no improvement after 3 m ,add short course of oral CS
 If still no improvement ,consider CT and evaluate as
surgical candidate
 If improved after 1 month switch to topical CS drops
Severe (VAS >7-10)
 Short course of oral CS +topical CS for 1 month
 If beneficial topical CS drops only and review after 3
months
 If no improvement consider CT and evaluate as
surgical candidate
JTTFP
Antibiotics:
Role is controversial; may be useful for acute exacerbation of chronic
disease
Intranasal corticosteroids:
May be modestly beneficial as adjunctive therapy
Antihistamines:
Possible role in CRS if underlying risk factor is allergic rhinitis
Topical and oral decongestants:
Prospective studies evaluating use are lacking
Antifungal agents:
Role has not yet been established
Take preventive measures to minimize symptoms and exacerbations of
CRS
Saline nasal irrigation
Good hand hygiene to prevent acute viral RS
Assess the patient for factors that could modify management
(eg, allergic rhinitis, cystic fibrosis, immunocompromised state,
ciliary dyskinesia, anatomic variation)
Conclusion
 Guidelines promulgated by different groups regarding CRS are not in
complete agreement regarding best practices
 The efficacy of intranasal CS has been well established by clinical trial data,
and guidelines advise their use in CRS
 Physicians have been overusing antibiotics which has been playing a role in
resistance
 There has been a push for clinical trials examining CRS with nasal polyposis,
CRS without nasal polyposis, and allergic fungal rhinosinusitis as distinct
entities; however, few such trials have been conducted to date, and more
data are needed to help clinicians treat these conditions appropriately.
 The value of antibiotics for treatment of CRS is still unproven
 References
 Scott Brown,BASCI guidelines ,
 Adjunct effect of loratadine in clearance. Br J Dis Chest 1984; 78:62–5
Primary ciliary dyskinesia. Acta Otorhinolaryngol Belg 2000; 54:317–
24. 20 Hurst JR, Donaldson GC, Wilkinson TM, Perera WR,
Wedzicha JA. Epidemiological relationships between the common
cold and exacerbation frequency in COPD. 27 Stanley P, MacWilliam
L, Greenstone M, Mackay I, Cole P. Efficacy of a saccharin test for
screening to detect abnormal
Ars sudha

More Related Content

What's hot

Aria
AriaAria
Journal club: efficacy and tolerability of systemic methylprednisolone in chi...
Journal club: efficacy and tolerability of systemic methylprednisolone in chi...Journal club: efficacy and tolerability of systemic methylprednisolone in chi...
Journal club: efficacy and tolerability of systemic methylprednisolone in chi...
Chulalongkorn Allergy and Clinical Immunology Research Group
 
In acute loss of asthma contro always systemic steroidsoe add increase the do...
In acute loss of asthma contro always systemic steroidsoe add increase the do...In acute loss of asthma contro always systemic steroidsoe add increase the do...
In acute loss of asthma contro always systemic steroidsoe add increase the do...
Envicon Medical Srl
 
Treatment of asthma
Treatment of asthmaTreatment of asthma
Treatment of asthma
Amir Mahmoud
 
What rhinitis and sinusitis and poliposis
What rhinitis and sinusitis and poliposisWhat rhinitis and sinusitis and poliposis
What rhinitis and sinusitis and poliposis
Envicon Medical Srl
 
Treatment of Asthma Exacerbations in the Pediatric Emergency Department
Treatment of Asthma Exacerbations in the Pediatric Emergency DepartmentTreatment of Asthma Exacerbations in the Pediatric Emergency Department
Treatment of Asthma Exacerbations in the Pediatric Emergency Department
jrhoffmann
 
BRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMA
BRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMABRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMA
BRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMA
Cristobal Buñuel
 
Stepwise Approach For Adjusting Asthma Treatment 2017
Stepwise Approach For Adjusting Asthma Treatment 2017 Stepwise Approach For Adjusting Asthma Treatment 2017
Stepwise Approach For Adjusting Asthma Treatment 2017
Ashraf ElAdawy
 
Vaccini
VacciniVaccini
Acute exacerbation of bronchial asthma dr. mukesh bhatt afpa_rdmc_06_20180422
Acute exacerbation of bronchial asthma dr. mukesh bhatt afpa_rdmc_06_20180422Acute exacerbation of bronchial asthma dr. mukesh bhatt afpa_rdmc_06_20180422
Acute exacerbation of bronchial asthma dr. mukesh bhatt afpa_rdmc_06_20180422
Parthiv Mehta
 
Acute asthma what is new?
Acute asthma  what is new?Acute asthma  what is new?
Acute asthma what is new?
Dr.Venugopalan Poovathum Parambil
 
Approach to asthma
Approach to asthmaApproach to asthma
Approach to asthma
Dr Praman Kushwah
 
Asthma in children 2014
Asthma in children 2014Asthma in children 2014
Asthma in children 2014
Khaled Saad
 
Common ocular allergy
Common ocular allergyCommon ocular allergy
GINA 2019 presentation
GINA 2019 presentationGINA 2019 presentation
GINA 2019 presentation
Dewan Shafiq
 
Evidence based Management of acute severe asthma
Evidence based Management of acute severe asthmaEvidence based Management of acute severe asthma
Evidence based Management of acute severe asthma
Dr Rakesh Kumar
 
Diagnosis &amp; management of status asthmaticus
Diagnosis &amp; management of status asthmaticusDiagnosis &amp; management of status asthmaticus
Diagnosis &amp; management of status asthmaticus
Sheela Aglecha
 
Asthma attack reatment abreviated
Asthma  attack reatment abreviatedAsthma  attack reatment abreviated
Asthma attack reatment abreviated
MohamedKhamis77
 
Asthma
Asthma Asthma
Non-allergic rhinitis
Non-allergic rhinitisNon-allergic rhinitis

What's hot (20)

Aria
AriaAria
Aria
 
Journal club: efficacy and tolerability of systemic methylprednisolone in chi...
Journal club: efficacy and tolerability of systemic methylprednisolone in chi...Journal club: efficacy and tolerability of systemic methylprednisolone in chi...
Journal club: efficacy and tolerability of systemic methylprednisolone in chi...
 
In acute loss of asthma contro always systemic steroidsoe add increase the do...
In acute loss of asthma contro always systemic steroidsoe add increase the do...In acute loss of asthma contro always systemic steroidsoe add increase the do...
In acute loss of asthma contro always systemic steroidsoe add increase the do...
 
Treatment of asthma
Treatment of asthmaTreatment of asthma
Treatment of asthma
 
What rhinitis and sinusitis and poliposis
What rhinitis and sinusitis and poliposisWhat rhinitis and sinusitis and poliposis
What rhinitis and sinusitis and poliposis
 
Treatment of Asthma Exacerbations in the Pediatric Emergency Department
Treatment of Asthma Exacerbations in the Pediatric Emergency DepartmentTreatment of Asthma Exacerbations in the Pediatric Emergency Department
Treatment of Asthma Exacerbations in the Pediatric Emergency Department
 
BRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMA
BRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMABRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMA
BRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMA
 
Stepwise Approach For Adjusting Asthma Treatment 2017
Stepwise Approach For Adjusting Asthma Treatment 2017 Stepwise Approach For Adjusting Asthma Treatment 2017
Stepwise Approach For Adjusting Asthma Treatment 2017
 
Vaccini
VacciniVaccini
Vaccini
 
Acute exacerbation of bronchial asthma dr. mukesh bhatt afpa_rdmc_06_20180422
Acute exacerbation of bronchial asthma dr. mukesh bhatt afpa_rdmc_06_20180422Acute exacerbation of bronchial asthma dr. mukesh bhatt afpa_rdmc_06_20180422
Acute exacerbation of bronchial asthma dr. mukesh bhatt afpa_rdmc_06_20180422
 
Acute asthma what is new?
Acute asthma  what is new?Acute asthma  what is new?
Acute asthma what is new?
 
Approach to asthma
Approach to asthmaApproach to asthma
Approach to asthma
 
Asthma in children 2014
Asthma in children 2014Asthma in children 2014
Asthma in children 2014
 
Common ocular allergy
Common ocular allergyCommon ocular allergy
Common ocular allergy
 
GINA 2019 presentation
GINA 2019 presentationGINA 2019 presentation
GINA 2019 presentation
 
Evidence based Management of acute severe asthma
Evidence based Management of acute severe asthmaEvidence based Management of acute severe asthma
Evidence based Management of acute severe asthma
 
Diagnosis &amp; management of status asthmaticus
Diagnosis &amp; management of status asthmaticusDiagnosis &amp; management of status asthmaticus
Diagnosis &amp; management of status asthmaticus
 
Asthma attack reatment abreviated
Asthma  attack reatment abreviatedAsthma  attack reatment abreviated
Asthma attack reatment abreviated
 
Asthma
Asthma Asthma
Asthma
 
Non-allergic rhinitis
Non-allergic rhinitisNon-allergic rhinitis
Non-allergic rhinitis
 

Similar to Ars sudha

Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
Nizam Uddin
 
D p t
D p t D p t
Common Pediatric Infections
Common Pediatric InfectionsCommon Pediatric Infections
Common Pediatric Infections
Dang Thanh Tuan
 
Common Pediatric Infections
Common Pediatric InfectionsCommon Pediatric Infections
Common Pediatric Infections
Dang Thanh Tuan
 
Allergic Rhinitis.pptx
Allergic Rhinitis.pptxAllergic Rhinitis.pptx
Allergic Rhinitis.pptx
h8wds7pgpv
 
Allergic Rhinitis.pptx
Allergic Rhinitis.pptxAllergic Rhinitis.pptx
Allergic Rhinitis.pptx
DoinaChiaburu1
 
Acute sinusitis
Acute sinusitisAcute sinusitis
Acute sinusitis
Elias Pour
 
Pharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospitalPharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospital
AhmanurSule5
 
Asthma a/c to pharmacy
Asthma a/c to pharmacyAsthma a/c to pharmacy
Asthma a/c to pharmacy
Ikram Khan Miwand Mohmand
 
Typhoid fever.ppt
Typhoid fever.pptTyphoid fever.ppt
Typhoid fever.ppt
MiliAgrawal10
 
Pediatric Respiratory Infections (3).gazi 2019.pptx
Pediatric Respiratory Infections (3).gazi 2019.pptxPediatric Respiratory Infections (3).gazi 2019.pptx
Pediatric Respiratory Infections (3).gazi 2019.pptx
GazmendBojaj1
 
Management of severe asthma an update 2014
Management of severe asthma an update 2014Management of severe asthma an update 2014
Management of severe asthma an update 2014
avicena1
 
Asthma
Asthma  Asthma
Asthma
Richin Koshy
 
INTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.pptINTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.ppt
Haramaya University
 
COVID_Management_14_April_2021.pptx
COVID_Management_14_April_2021.pptxCOVID_Management_14_April_2021.pptx
COVID_Management_14_April_2021.pptx
SidramKhyade
 
Pulmonology critical care- archer step3 lectures
Pulmonology  critical care- archer step3 lecturesPulmonology  critical care- archer step3 lectures
Pulmonology critical care- archer step3 lectures
Archer Review USMLE and NCLEX
 
AERD: Diagnosis and Treatment
AERD: Diagnosis and TreatmentAERD: Diagnosis and Treatment
AERD: Diagnosis and Treatment
KSAAI
 
Asthma
AsthmaAsthma
Asthma
Hardik Vora
 
1 pharyngo tonsilitis
1 pharyngo tonsilitis1 pharyngo tonsilitis
1 pharyngo tonsilitis
mandar haval
 
Asthma a clinical review and its management
Asthma  a clinical review and its managementAsthma  a clinical review and its management
Asthma a clinical review and its management
Nani Karnam Vinayakam
 

Similar to Ars sudha (20)

Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
 
D p t
D p t D p t
D p t
 
Common Pediatric Infections
Common Pediatric InfectionsCommon Pediatric Infections
Common Pediatric Infections
 
Common Pediatric Infections
Common Pediatric InfectionsCommon Pediatric Infections
Common Pediatric Infections
 
Allergic Rhinitis.pptx
Allergic Rhinitis.pptxAllergic Rhinitis.pptx
Allergic Rhinitis.pptx
 
Allergic Rhinitis.pptx
Allergic Rhinitis.pptxAllergic Rhinitis.pptx
Allergic Rhinitis.pptx
 
Acute sinusitis
Acute sinusitisAcute sinusitis
Acute sinusitis
 
Pharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospitalPharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospital
 
Asthma a/c to pharmacy
Asthma a/c to pharmacyAsthma a/c to pharmacy
Asthma a/c to pharmacy
 
Typhoid fever.ppt
Typhoid fever.pptTyphoid fever.ppt
Typhoid fever.ppt
 
Pediatric Respiratory Infections (3).gazi 2019.pptx
Pediatric Respiratory Infections (3).gazi 2019.pptxPediatric Respiratory Infections (3).gazi 2019.pptx
Pediatric Respiratory Infections (3).gazi 2019.pptx
 
Management of severe asthma an update 2014
Management of severe asthma an update 2014Management of severe asthma an update 2014
Management of severe asthma an update 2014
 
Asthma
Asthma  Asthma
Asthma
 
INTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.pptINTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.ppt
 
COVID_Management_14_April_2021.pptx
COVID_Management_14_April_2021.pptxCOVID_Management_14_April_2021.pptx
COVID_Management_14_April_2021.pptx
 
Pulmonology critical care- archer step3 lectures
Pulmonology  critical care- archer step3 lecturesPulmonology  critical care- archer step3 lectures
Pulmonology critical care- archer step3 lectures
 
AERD: Diagnosis and Treatment
AERD: Diagnosis and TreatmentAERD: Diagnosis and Treatment
AERD: Diagnosis and Treatment
 
Asthma
AsthmaAsthma
Asthma
 
1 pharyngo tonsilitis
1 pharyngo tonsilitis1 pharyngo tonsilitis
1 pharyngo tonsilitis
 
Asthma a clinical review and its management
Asthma  a clinical review and its managementAsthma  a clinical review and its management
Asthma a clinical review and its management
 

Recently uploaded

Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loopLOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
debosmitaasanyal1
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
Gokuldas Hospital
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
Gokuldas Hospital
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
BrissaOrtiz3
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 

Recently uploaded (20)

Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loopLOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 

Ars sudha

  • 1. Medical management By Dr.Sudha Shahi Dept of ENT Head and Neck Surgery Bir Hospital ,NAMS Kathmandu,Nepal
  • 2.  “When we consider the quality of life impact from RS related symptoms and the associated emotional and functional impairments it can be assumed that RS has a dramatic impact on peoples lives and in productivity of life.”
  • 3.
  • 4.
  • 5.
  • 6. Brief Recall: Rhinosinusitis- Group of disorders characterised by Inflammation of mucosa of nose and paranasal sinuses.
  • 8. Infection Acute( 7 days to <4wks) Viral (majority of cases) Subacute(4-12wks) Chronic(>12wks) Recurrent acute – 4 or more episodes per year, with resolution of symptoms between attacks Acute Exacerbation of Chronic- Sudden worsening of CRS with return to baseline after
  • 9. Others Occupational irritants and allergens Vasculitis/granulomatous/autoimmune Aspirin sensitivity Allergic fungal sinusitis Atrophic rhinitis
  • 10.  Others NARES Drug induced, rhinitis medicamentosa Irritant-induced rhinitis GERD Underlying diseases(cystic fibrosis, ciliary immotility) Structural  Osteomeatal complex  Deviated nasal septum  Hypertrophic turbinates Idiopathic
  • 12. Allergic Rhinitis  Allergen avoidance  Antihistamines:  First generation mostly avoided d/t sedative psychomotor retardation and learning impairment d/t BBB crossing nature of it as compared to Cetrizine,Fexofenadine,desloratidine .Also possess some antiinflammatory effect  Topical Glucorticosteroid: Best is started before allergen exposure . Reduce inflammation,hyperreactivity and sense of smell
  • 13. Sodium chromoglycate : Used for children below 4 yrs in whom topical corticoseroid is not used often Decongestants: Reduce nasal obstruction but long term use might cause rhinitis medicamentosa Ipratropium bromide: Symptomatic relief in rhinorrhea but careful use in glaucoma and prostatism and might worsen dry eyes and mouth
  • 14. Systemic Corticosteroids Occasional intermittent use combined with topical CS Antileukotrienes: Effective against congestion and mucus production.Combined with antihistamine has better benefits. Nasal douching : Helps provide symptomatic relief and clear up the sinuses
  • 15. Immunotherapy: Only in selective patients with limited spectrum of allergies ~ 40% reduction in symptoms and ~80% reduction in rescue medication requirements Also helpful in associated bronchial Asthma Nevertheless patients with chronic Asthma are excluded from the treatment due to risk of many side effects
  • 16. Inclusion criteria  IgE-mediated disease (+SPT/RAST)  Inability to avoid allergen  Inadequacy of drug  Limited spectrum of allergies (one or two)  Patients who understand risks and limitations of treatment Contraindications  Coexistent asthma  Patients taking beta- blockers  Other medical/immunologic  Small children (less than five years)  Pregnancy (maintenance therapy may be continued in pregnancy)
  • 17. Novel advances  Sublingual immunotherapy  Bacterial DNA sequences conjugated with allergen induces preferential TH1 response and protective T cell response
  • 18.  Surgery:  Very limited role and required only in conditions where there is marked septal deviation or bony turbinate enlargement which makes topical nasal sprays usage difficult.
  • 21. Children Adults Streptococcus pneumoniae (30-43%) Haemophilus influenzae (20-28%) Moraxella catarrhalis (20-28%) Other Streptococcus species (5-7%) Anaerobes(5-7%) Streptococcus pneumoniae (20-43%) Haemophilus influenzae (22-35%) Streptococcus species (3-9%) Anaerobes (0-9%) Moraxella catarrhalis (2-10%) Staphylococcus aureus (0-8%) Others(4%)
  • 22. Common for all types of Acute RS: Hydration Long-acting topical nasal decongestant Nasal saline applied with nasal irrigation device Topical nasal CCS
  • 23.
  • 24. Antibiotics in Acute bacterial rhinosinusitis Don’t treat common viral cold with antibiotic Reserve for severe, presumably bacterial Rhinosinusitis symptoms past 7-10 days: Antibiotics X 7-14 days (until asymptomatic +5-7 days). Choices: Amoxicillin/clavulanate, Cephalosporin, Clarithromycin
  • 25. First choice: Amoxicillin/clavulate or cephalosporin Good second choice: Clarithromycin (Azithromycin, 5-0-(5), may also be quite useful) Back-ups: Quinolones Use Metronidazole plus one of the above or clindamycin when gram negative is suspected Topical mupirocin very useful in select cases
  • 26. EPOS JTFPP CPG AS Uncomp icated AVRS Mild Disease- Symptoms lasting <5d or improving thereafter Decongestants ,Saline or analgesics Moderately severe- Symptoms lasting >.5d or increasing Add topical corticosteroids If no improvement after 14 d Reconsider rediagnosis Consider nasal endoscopy Culture/imaging Consider antibiotics if necessary Severe Disease- Severe pain and temp >38 Add antibiotics and topical corticosteroids for 7-14 days (expected results in 48 hrs) 7-10 days course of watchful waiting Antibiotics are strongly discouraged Management primarily symptomatic Analgesics and antipyretics Oral or topical decongestants Topical nasal CS(Optional)
  • 27. EPOS JTFFP CPG AS Uncomplicate d ABRS Mild Disease- Symptoms lasting <5d or improving thereafter Decongestants ,Saline or analgesics Moderately severe- Symptoms lasting >.5d or increasing Add topical corticosteroids If no improvement after 14 d Reconsider rediagnosis Consider nasal endoscopy Culture/imaging Consider antibiotics if necessary Severe Disease- Severe pain and temp >38 Add antibiotics and topical corticosteroids for 7-14 days (expected results in 48 hrs) Antibiotics 10-14 d Choice of agent based on likely pathogen consistent with clinical history Consider patients with severe signs and symptoms at any time of the disease (worsening after 3-5 days,temp>38, severe facial pain,unilateral facial swelling ,sinus tenderness) Assess pain and analgesics accordingly Watchful waiting ( without antibiotic i symptom< 7d)or mild disease or if pt likely to F/U Initiate Antibiotics i no improvement after 7d or if it worsen (Amoxy firs line)Antibiotics if severe disease Antihistamine Donot use if nonatopic symptomatic relief i recommended
  • 28. EPOS JTFFP CPS AG ARS in general Intranasal corticosteroids Oral CS in severe disease Antihistamines only in allergic and Decongestants Intranasal CS modestly benefitial as adjunctive therapy in patients with reccurent disease Antihistamines No data to recommend use Topical oral decongestants Do not use since prospective study ecaluating use are lacking Topical CS optional Decongestant optional Nasal saline irrigation optional
  • 29. Conclusion  Guidelines promulgated by 5 major groups regarding acute rhinosinusitis (ARS)  The efficacy of intranasal corticosteroids has been well established by clinical trial data, and guidelines advise their use in ARS  Physicians have been overusing antibiotics which has been playing a role in resistance
  • 30.  The aim of treatment is to reduce signs and symptoms ,quality of life of patient and prevent the recurrence.
  • 31. Chronic inflamed mucosa Neutrophils and mononuclear cells in CRSsNP Eosinophils in CRSwNP Possible chronic infection Bacteria Fungi Superantigens Biofilms Osteitis
  • 32. Children Adults Anaerobes Other Streptococcus species Staphylococcus aureus Streptococcus pneumoniae Haemophilus influenzae Pseudomonas aeruginosa Anaerobes Other Streptococcus species Haemophilus influenzae Staphylococcus aureus Streptococcus pneumoniae Moraxella catarrhalis Common organisms in CRS
  • 33. Chronic Rhinosinusitis Nasal Polyps Nasal Polyps The spectrum of sinus disease Rhinosinusitis - Eosinophils +
  • 34. Treatment Few well-conducted clinical trials in chronic rhinosinusitis. Further studies are needed in well- characterized patients. Based on the evidence available initial therapy is medical Aim to reduce symptoms and signs decrease morbidity and prevent disease progression or recurrence. CRS usually responds incompletely to therapy and may need to be continued long-term
  • 35. Hydration (6 - 8 glasses of water per day) Antibiotics only if clear evidence of infection: use X 14-21+ days (until asymptomatic +7 days). Choices: cephalosporin, amoxicillin/clavulanate, clarithromycin, quinalone Long-acting nasal decongestant, BID X 3-7 days (oxymetazoline) Nasal saline with nasal irrigation device Topical nasal CCS Reduce to lowest effective dose, to maintain remission
  • 36. Prevalence approx. 2- 4%, 25% of CRS Asthma in approx. 40-65% Aspirin sensitivity in 10-15% Mixed cellular infiltrate with prominent eosinophilia in 90% Inflammation with  local IgE production  increased IL-5, eotaxin, cys-LTs and ECP
  • 37.
  • 38. Treatment of underlying condition Continue treatment of sinusitis Topical corticosteroids Pulmicort, budesonide Budesonide solution (Pulmicort Respules) Fluticasone (Flovent Systemic corticosteroids Prednisone 20-30 mg Kaliner MA. Current Review of Allergic Diseases. Philadelphia, Pa: Current Medicine, Inc., 1999.
  • 39.  Antibiotics  Long term prophylaxis with macrolids group of drug (8 wks )found to reduce the polyp size ot 50% in 21 patients and better response in ptns with normal IgE levels and inversely proportional in eosinophil count in blood and mucosa
  • 40. Mupiricin ointment Topically or dissolved in sinus lavage Consider oral or topical anti-fungal treatment Possible benefits in paediatric Upper airway infcetion Needs more studies Polypectomy
  • 41. Medical polypectomy  All patients should have a trial of medical treatment before surgery unless the nature of the polyps is in doubt.  Smaller polyps may respond to topical corticosteroid only.  Larger polyps may respond to a medical polypectomy
  • 42. Medical polypectomy Prednisolone 0.5mg/kg each morning for 5–10 days PLUS Betamethasone nasal drops two drops per nostril tds in the ‘head upside down’ position for 5 days, then twice daily until the bottle runs out  Maintenance therapy with fluticasone (drops, spray) or mometasone (spray) is recommended as these have lower bioavailability, unlike betamethasone nasal drops .
  • 43.  All forms of topical INS may delay the re-growth of nasal polyps. Polyps tend to recur, and it is recommended that treatment is continued for the long-term.  However, no evidence for how long treatment should be continued although this will vary, with more aggressive inflammatory polyps rich in eosinophils and IL-5 requiring prolonged treatment.
  • 44. Surgery  A randomized prospective study of patients with polypoid or non-polypoid CRS demonstrated that there was no difference between patients who received medical treatment (topical corticosteroid, nasal douching and long-term erythromycin) compared with those who underwent endoscopic sinus surgery combined with topical nasal steroids.  , Clinical and Experimental)
  • 46.
  • 47. Allergen avoidance  There is no strong evidence regarding its effectiveness in CRS but mostly in cases with positive allergic history together with positive SPT it might be useful.
  • 48. Nasal douching Safe, inexpensive,symptomatic relief Adverse events Sodium load should be considered in hypertensive patients. Place in therapy Addition to therapy in chronic rhinosinusitis, nasal polyposis and rhinitis. Effective in primary ciliary dyskinesia
  • 49. Neti pots The Neti pot originated in India in Ayurvedic medicine.( VALIDATED BY SCIENTIFIC EVIDENCE) Neti is Sanskrit for “nasal cleansing.” Nasal irrigation provides short-term symptomatic relief and may improve nasal mucociliary clearance. It removes mucus not only from the nose but also from the maxillary and ethmoid sinuses. BUT one should be careful not to overdo it.
  • 50.
  • 51.
  • 52. Topical intra-nasal corticosteroids  Act by suppression of inflammation at multiple points in the inflammatory cascade . Nasal drops are preferable for nasal polyposis and probably also for chronic rhinosinusitis.  These should be used in the ‘head upside down’ position in order to reach the ostiomeatal complex (OMC), 50% of ptns not responding to topical sprays are responsive to fluticasone nasules
  • 53.
  • 54.  Adverse events  Local nasal irritation, sore throat and epistaxis (10% ) (Benzalkonium chloride)  Hypothalmic-pituitary axis suppression  Raised intra-ocular pressure (glaucoma)
  • 55.  Place in therapy First-line therapy for rhinosinusitis. Topical steroid drops should be used initially in nasal polyposis and in cases with severe obstruction.Routinely used in long term and reduce the recurrence of nasal polyps.  A suggested regime for adults is 0.5mg/kg
  • 56. Used for:  Severe nasal obstruction  Short-term rescue medication for uncontrolled symptoms on conventional pharmacotherapy
  • 57.
  • 58. Systemic glucocorticosteroids. Oral corticosteroids should be used briefly and always in combination with a topical nasal corticosteroid.
  • 59.  Intra-nasal decongestants. The a1-agonist ephedrine and a2-agonist xylometazoline are sympathomimetics( increase nasal vasoconstriction). Combined with a topical corticosteroid such as Dexa- Rhinaspray duoTM, short term use is helpful in exacerbations of rhinosinusitis with nasal blockage
  • 60.  Adverse events  Regular use can lead to rhinitis medicamentosa with tachyphylaxis rebound effect.Nasal irritation may increase rhinorrhoea.  Place in therapy Brief use of 10 days is advised o To avoid rebound effect for eustachian tube dysfunction when flying o In children with acute otitis media to relieve middle ear pain/pressure post –URTI o To reduce nasal/sinus congestion o To increase nasal patency before the intranasal administration of nasal steroids.
  • 61. Antibiotics  Role in CRS is still controversial Two routes;  Topical –Abandoned due to incidence of hyposmia but use of tobramycin instilled into maxillary sinuses in cystic fibrosis is helpful  Benefitial in upper airway diseases in children  Short-term (2 weeks) can be used for AE of rhinosinusitis with or without the guidance of middle meatal swabs
  • 62.  Long term prophylaxis  Trials of long-term oral antibiotics (>12 weeks), especially macrolides, have demonstrated symptomatic and objective improvement similar to endoscopic sinus surgery  Reduction in mortality from diffuse panbronchitis and improved sinus symptoms  The improvement shown increases with time and may relate to anti-inflammatory reactions in macrolides.
  • 63. Anti-leukotrienes There are no RCTs on the use of anti-leukotrienes in rhinosinusitis, but efficacy in nasal polyposis has been demonstrated.(`50 %respond to some degree) Adverse events Usually well tolerated; occasional headache, gastrointestinal symptoms or rashes. Occasional reports of Churg-Strauss syndrome which may relate more to steroid withdrawal rather than a direct effect of the drug, although further long-term evaluation is needed.
  • 64. Place in therapy Anti-leukotrienes may be used in patients with aspirin- sensitive rhinosinusitis, asthma and nasal polyposis. Some patients with aspirin sensitivity appear to show marked improvement.
  • 65. Aspirin desensitisation  Oral aspirin desensitization followed by regular daily dosing may cause significant improvement.  There is some evidence suggesting that oral doses as low as 100mg daily maybe effective and this could potentially circumvent some of the adverse effects associated with oral aspirin.  However, side-effects including gastrointestinal bleeding at high doses .The efficacy of the regular administration of topical intranasal lysine aspirin therapy remains under investigation.
  • 66. Nasal  Lysine aspirin the soluble aspirin used for diagnosis of aspirin sensitivity has found to have resulted into prolonged polyp free interval in both aspirin sensitive and aspirin tolerant patients.  It has shown to be associated with reduction of cysteinyl leukotriene receptors which are upregualted in nasal mucosa of aspirin sensitive individuals.
  • 67. Immunotherapy  Immunoglobulin replacement therapy in humoral deficiency syndromes( frank hypogammaglobinemia to IgA and other subclasses deficiencies) Bacterial vaccines  Used previously but no strong evidence of benefitial effect
  • 68.  Other therapies Diuretics  Frusemide found to reduce the recurrence of polyps if administered nasally to post polypectomy patients over a prolonged periods  Similarly amiloride used in cystic fibrosis also suggested as topical therapy for nasal polyps
  • 69. Azelastine: An open study suggests that this may have some benefit in nasal polyposis Nitric Oxide donors: NO has bactericidal properties and is manufactured inPNS. NO levels are raised in inflammation but decreased in CRSprobabaly due to ostiomeatal complex obstruction. hence increased. NO levels is a landmark for successful therapy. eg.Arginine
  • 70.  Diet  Alcohol,preservative,high salicylate food exacerbate  Milk mucus promoter
  • 71.  In case of ocupational ,food induced,drug induced,irritant induced avoidance of the causitive factor  Intranasal anticholinergics (Ipratropium bromide)  Nasal decongestants  Topical steroids and antihistamines  Azelastine  Silver nitrate and botulinum if no response to conventional therapy  Intranasl capsacain once daily for 5 weeks  Surgical aproach if turbinate hypertrophy with resistant with medical response  Ethmoid and Vidian neurectomies
  • 72. Allergic fungal sinusitis Aggressive nasal Rx Budesonide nasal washings, 500 ug BID Itraconazole, oral 100 mg BID x 6 months 100 mg QD x 12 months Monitor LFT, IgE Q 3 mos Consider surgery if unresponsive Surgery with the removal of all affected tissue, followed by topical corticosteroids
  • 73. Fungal rhinosinusitis Open studies of douching with antifungals such as amphotericin have been reported as beneficial  Antifungals  Placebo-controlled trials of amphotericin nasal douching are negative .  Oral terbinafine has also failed to show any activity under double-blind conditions
  • 74. Churg-Strauss syndrome  This is a combination of severe asthma, nasal polyposis, eosinophilia and eosinophilic vasculitis with granulomas. It should be suspected in patients with severe disease requiring frequent courses of oral corticosteroids. About 50% of patients are ANCA positive.). If the diagnosis of Churg-Strauss syndrome is suspected, specialist referral to a vasculitis clinic is advisable for further mangement
  • 76. Nasal Tuberculosis Lupus vulgaris(nodular forms),Ulcerative forms,sinus granuloma  Tubercular treatment ; 4 drug regimen 4HRZE+4HR Syphilis TT;Parenteral penicillin preferred DOC  Local treatment includes crust removal,alkaline nasal douches ,yellow mercury oxide oint locally
  • 77.  Hereditary syphillis  Local cleansing  Yellow mercury oxide oint.  Nasal douching  Antisyphillitic medication  Leprosy  Direct intranasal administration of rifampin reduce M.Leprae load much faster than when given orally  Rifamicin 600mg first 2 days on alternate days three times aweek  Clofazimine 100mg alternate day three times a week  Dapsone 100mg daily
  • 78. Atrophic Rhinitis  Regular nasal cleansing  Nasal douching with hypertonic alkaline saline (sodium bicarb:Sodium diborate:sodium chloride)1;1;2 in 280 ml of water followed by solution of 25 percent glucose in glycerine to inhibit proteolytic organisms  Human placental extract systemically and locally  Rifampicin 600mg oral for 12 weeks good results
  • 79.  Underlying diseases(Cystic fibrosis,Wegners granulomatosis) Azathioprine ,cyclophosphamide or cotrimoxazole in addition to the symtomatic management
  • 80. Structural  Obstruction of Osteomeatal complex  Decongestant  Nasal douching  Topical CS  Review at 6 wks
  • 81. Further medical therapy  Oral CS few days plus Topical for long term  For nasal polyposis  Trial of leukotriene for nasal polyposis  Antibiotics  Aspirin
  • 82. Rhinosinusitis in children Common problem;may be related to underlying immune deficiency (innate or acquired) or to allergy Like OME, usually resolves with maturation (~7 years) Medical treatment including douching should be instigated, with surgery reserved for acute severe problems or for those patients with severe chronic symptoms not responding to medical therapy .
  • 83.
  • 84. Few clinial studies in Rhinosinusitis and their guidelines brief comparision
  • 85. EPOS  CRSsNP  Mild(VAS 0-3)  Topical CS  Nasal Lavage if failure after 3 months treat as moderate or severe  Moderate /severe(VAS >3-10)  Topical CS  Nasal lavage  Longterm macrolide therapy  Culture  Cases that improve  Follow up + nasal lavage ,topical CS +/- long term macrolide therapy Mild = VAS 0 - 3 Moderate = >3 - 7 Severe = VAS >7 - 10
  • 86.  CRScNP Mild (VAS 0-3)  TopicalCS sprayfor 3 months  if benefitial continue and review every 6 months  If no improvement ,add short course of oral CS  If still n oimprovement ,consider CT assess as surgical candidate  If improved after 1 month switch to topical CS drops,review after 3 months
  • 87. Moderate (VAS 3-7)  Topical CS drops for 3 months  if beneficial continue and review every 6 months  If no improvement after 3 m ,add short course of oral CS  If still no improvement ,consider CT and evaluate as surgical candidate  If improved after 1 month switch to topical CS drops
  • 88. Severe (VAS >7-10)  Short course of oral CS +topical CS for 1 month  If beneficial topical CS drops only and review after 3 months  If no improvement consider CT and evaluate as surgical candidate
  • 89. JTTFP Antibiotics: Role is controversial; may be useful for acute exacerbation of chronic disease Intranasal corticosteroids: May be modestly beneficial as adjunctive therapy Antihistamines: Possible role in CRS if underlying risk factor is allergic rhinitis Topical and oral decongestants: Prospective studies evaluating use are lacking Antifungal agents: Role has not yet been established
  • 90. Take preventive measures to minimize symptoms and exacerbations of CRS Saline nasal irrigation Good hand hygiene to prevent acute viral RS Assess the patient for factors that could modify management (eg, allergic rhinitis, cystic fibrosis, immunocompromised state, ciliary dyskinesia, anatomic variation)
  • 91. Conclusion  Guidelines promulgated by different groups regarding CRS are not in complete agreement regarding best practices  The efficacy of intranasal CS has been well established by clinical trial data, and guidelines advise their use in CRS  Physicians have been overusing antibiotics which has been playing a role in resistance  There has been a push for clinical trials examining CRS with nasal polyposis, CRS without nasal polyposis, and allergic fungal rhinosinusitis as distinct entities; however, few such trials have been conducted to date, and more data are needed to help clinicians treat these conditions appropriately.  The value of antibiotics for treatment of CRS is still unproven
  • 92.  References  Scott Brown,BASCI guidelines ,  Adjunct effect of loratadine in clearance. Br J Dis Chest 1984; 78:62–5 Primary ciliary dyskinesia. Acta Otorhinolaryngol Belg 2000; 54:317– 24. 20 Hurst JR, Donaldson GC, Wilkinson TM, Perera WR, Wedzicha JA. Epidemiological relationships between the common cold and exacerbation frequency in COPD. 27 Stanley P, MacWilliam L, Greenstone M, Mackay I, Cole P. Efficacy of a saccharin test for screening to detect abnormal